A Novel L-Phenylalanine Dipeptide Inhibits the Growth and Metastasis of Prostate Cancer Cells via Targeting DUSP1 and

Lanlan Li1,2,3, Mingfei Yang1, Jia Yu1,2

  • 1State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China.

Insights

A novel compound, HXL131, derived from Matijin-Su, effectively inhibits prostate cancer (PCa) growth and metastasis. It targets key proteins DUSP1 and TNFSF9, offering a promising new avenue for PCa treatment.

Area of Science:

  • Pharmacology and Natural Products Chemistry
  • Oncology and Cancer Therapeutics

Background:

  • Prostate cancer (PCa) treatment faces challenges like drug resistance and recurrence with current therapies.
  • Natural products offer a source for novel anti-tumor compounds with potentially higher efficacy and lower toxicity.
  • Matijin-Su (MTS) derivatives, including HXL131, show significant anti-cancer potential.

Purpose of the Study:

  • To investigate the anti-prostate cancer effects of the MTS derivative HXL131 on human PCa cell lines (PC3).
  • To elucidate the molecular mechanisms underlying HXL131's inhibition of PCa growth and metastasis.
  • To identify potential molecular targets of HXL131.

Main Methods:

  • In vitro experiments assessing cell proliferation, apoptosis, cell cycle, and migration.
  • Proteomic analysis and Western blot to identify protein expression changes.
  • Molecular docking, CETSA, and gene silencing to validate molecular targets.

Main Results:

  • HXL131 dose-dependently inhibited PC3 cell proliferation, induced apoptosis, and arrested the cell cycle at G2/M phase.
  • HXL131 significantly reduced PC3 cell migration capacity.
  • HXL131 modulated the expression of key proteins involved in proliferation, apoptosis, cell cycle, and migration, notably up-regulating DUSP1 and TNFSF9.

Conclusions:

  • HXL131 demonstrates potent anti-prostate cancer activity by inhibiting tumor cell growth and metastasis.
  • The anti-cancer effects of HXL131 are mediated through the regulation of DUSP1 and TNFSF9 expression.
  • HXL131 represents a promising therapeutic candidate for prostate cancer treatment.